Myriad Genetics (MYGN) Reports In-Line Q4 EPS

February 24, 2025 5:02 PM UTC

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $211 million versus the consensus estimate of $213.31 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings, Maynard Um, Mark Zuckerberg, ARK